Juno Therapeutics Inc. (JUNO)

86.96
0.09 0.10
Prev Close 86.87
Open 86.97
Day Low/High 86.90 / 87.01
52 Wk Low/High 19.62 / 87.01
Volume 3.70M
Avg Volume 4.51M
Exchange
Shares Outstanding 116.11M
Market Cap 10.10B
EPS -4.10
Div & Yield N.A. (N.A)

Latest News

Getting Ready for Biotech Earnings

Getting Ready for Biotech Earnings

Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.

Possible Biotech Takeout Plays

Possible Biotech Takeout Plays

A look at possible second-quarter M&A activity in the biotech sector.

Bret Jensen's Biotech Mailbag

Bret Jensen's Biotech Mailbag

We'll answer two of the common questions we have received so far in March.

Celgene Receives Antitrust Clearance For Juno Acquisition

Celgene Receives Antitrust Clearance For Juno Acquisition

Celgene Corporation (NASDAQ:CELG) today announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with respect to the previously announced tender offer by Celgene's...

Corporate America Is Sitting on $5 Trillion of M&A Firepower

Corporate America Is Sitting on $5 Trillion of M&A Firepower

Wow. Corporate America is sitting on massive amounts of cash that could be unleashed on deals, according to new research from Citi.

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

A steeper fall might cause both buyers and sellers to re-think potential deals, but so far that doesn't seem to be the case yet.

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Vertex Pharmaceuticals, Amgen and Johnson and Johnson were among the big movers in the biotech and pharmaceutical sectors.

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside

The biotech sector has seen a big rally, but there are still opportunities.

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

Outside of oncology, the rare disease area is a good target for M&A in 2018.

Circle These Biotech Acquisition Candidates

Circle These Biotech Acquisition Candidates

Outside of oncology, the rare disease area is a good target for M&A in 2018.

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.

Celgene Says Juno, Impact Deals Won't Be Its Last

Celgene Says Juno, Impact Deals Won't Be Its Last

The biopharmaceutical giant's top executive says the company will continue to aggressively invest in R&D and deploy capital to acquire or license assets.

The Law Offices Of Vincent Wong Reminds Investors Of An Investigation Of Juno Therapeutics, Inc. In Connection With The Sale Of The Company To Celgene Corp.

The Law Offices Of Vincent Wong Reminds Investors Of An Investigation Of Juno Therapeutics, Inc. In Connection With The Sale Of The Company To Celgene Corp.

The Law Offices of Vincent Wong are investigating the Board of Directors of Juno Therapeutics, Inc.

The Law Offices Of Vincent Wong Notifies Investors Of An Investigation Of Juno Therapeutics, Inc. In Connection With The Sale Of The Company To Celgene Corp.

The Law Offices Of Vincent Wong Notifies Investors Of An Investigation Of Juno Therapeutics, Inc. In Connection With The Sale Of The Company To Celgene Corp.

The Law Offices of Vincent Wong are investigating the Board of Directors of Juno Therapeutics, Inc.

Tax Reform's Impact on the Economy

Tax Reform's Impact on the Economy

Consumer spending should be more than solid given wage increases.

S&P 500 Will Be Gripped by Classic Investor Euphoria This Year in Surge to 3,000

S&P 500 Will Be Gripped by Classic Investor Euphoria This Year in Surge to 3,000

Is there anything that could derail the stock market's momentum this year? The answer is probably not, suggests Bank of America.

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors Of An Investigation Concerning Whether The Sale Of Juno Therapeutics, Inc. To Celgene Corp. Is Fair To Shareholders

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors Of An Investigation Concerning Whether The Sale Of Juno Therapeutics, Inc. To Celgene Corp. Is Fair To Shareholders

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Juno Therapeutics, Inc.

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

Here's what you need to know now for Monday, Jan. 22.

Dow, S&P 500 and Nasdaq Post New Records as Senate Reaches Deal to End Shutdown

Dow, S&P 500 and Nasdaq Post New Records as Senate Reaches Deal to End Shutdown

Stocks hit fresh records on Monday after a deal is reached to end the three-day government shutdown.

Closing Bell: LIVE MARKETS BLOG

Closing Bell: LIVE MARKETS BLOG

All three indices closed the day in record territory.

JUNO THERAPEUTICS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Believes The Acquisition By Celgene Corporation May Be Unfair To Shareholders

JUNO THERAPEUTICS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Believes The Acquisition By Celgene Corporation May Be Unfair To Shareholders

Former United States Securities and Exchange Commission attorney Willie Briscoe is investigating potential claims against the Board of Directors of Juno Therapeutics, Inc.

Video: Jim Cramer on the Eagles, Celgene, Juno Therapeutics and Netflix

Video: Jim Cramer on the Eagles, Celgene, Juno Therapeutics and Netflix

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts to Monday's trending topics.

In This Booming Stock Market, Think Like a Programmer Not a Critic

In This Booming Stock Market, Think Like a Programmer Not a Critic

What drives the trading action are structural issues, not macroeconomic news events or political drama.

Immunotherapy Stocks Power Higher on Celgene-Juno Deal

Immunotherapy Stocks Power Higher on Celgene-Juno Deal

Shares of immunotherapy companies including Ziopharm Oncology and Fate Therapeutics rose early on Monday on the heels of Juno Therapeutics' announced sale to Celgene.